Categories Finance

Deutsche Bank plans a major overhaul of operations

Deutsche Bank AG (DB) is planning a major overhaul of its operations after reporting disappointing results for its first quarter of 2018. These actions will involve a slow retreat from the US and more focus on Europe. It will also result in considerable job cuts within its US operations.

Deutsche Bank reported net earnings of EUR120 million or $146 million for the first quarter of 2018, a 79% decrease compared to EUR575 million for the same period last year. The bank also saw a 5% decline in total revenues, along with revenue decreases in all divisions. The results were nowhere near analyst estimates.

CEO Christian Sewing, who took charge earlier this month, described the shareholder returns as unacceptable and said the results called for immediate action. As part of this effort, Deutsche Bank is planning to reduce its bonds and equities operations in the US and Asia and invest more in its European business.

Deutsche Bank
Image courtesy: Lucas Kauffman, Wikimedia Commons

The bank feels it is necessary to move from the unprofitable investment banking business to commercial and retail banking and asset management and to concentrate more in the German and European markets. Restructuring costs are likely to increase significantly this year. Deutsche Bank is said to be looking to cut its US workforce by 10% and is believed to have fired nearly 400 investment bankers with more to follow.

For more than two decades, Deutsche Bank has tried to succeed in the US as a global investment bank without much triumph. The company has faced tough competition from JPMorgan (JPM) and Goldman Sachs (GS). It is not yet clear how the new strategy will benefit Deutsche Bank as it is likely to face competition in Germany too from UBS and Credit Suisse, which hold strong position in the region. In any case, for now, it seems Deutsche Bank is ready to move away from Wall Street.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top